Protara Therapeutics, Inc. PRTO Cash Flow

Protara therapeutics, inc. (PRTO)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net Loss
-18,521	-14,992	-18,641	-21,615	-21,179	-20,729	-21,021	-28,818	-29,547	-29,964	-31,375	-26,175	-28,472	-28,526	-27,906	-26,182	-23,349	-21,377	-7,802	-7,600	-5,091	-3,342	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	73	-	42	34	31	30	0	0	0
Amortization of premium/discount on available-for-sale securities
-	4	20	41	58	51	35	17	3	2	-21	-61	-99	-131	-179	-307	-489	-651	-592	-439	-224	-30	0	0	0
Accretion of discount and debt issuance cost of convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	742	0	0	0
Unrealized loss on forward foreign currency contracts included in net income
-	-	-	-	-	-	-	-	-	-	-	-	-	127	16	-300	-359	-537	0	0	0	-	-	-	-
Foreign currency remeasurement (loss)
-	-	-	-	-	25	394	477	250	173	-278	-334	-45	-76	-40	-90	-47	-75	0	0	0	-	-	-	-
Stock based compensation
2,960	943	1,759	2,567	3,388	3,429	3,415	3,258	3,203	3,227	3,303	3,243	3,322	3,343	3,169	3,093	2,623	2,164	1,719	1,293	849	459	0	0	0
Amortization of operating lease right-of-use asset
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation
154	279	311	250	257	115	116	132	140	148	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	81	0	0	0
Prepaid expenses and other current assets
-182	-608	-634	-495	-369	-141	163	-430	-140	-297	-1,315	-49	-193	-246	738	20	671	899	-1,092	-100	599	961	0	0	0
Accounts payable
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use asset
-	-200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest receivable
-	-17	-62	-50	-30	-49	0	0	0	-	-	-	-	26	-228	-140	-247	32	201	197	320	0	0	0	0
Accounts payable and accrued expenses
-	-2,497	-921	-176	-5,787	-6,162	-6,560	-1,906	5,997	4,161	4,219	-599	-616	1,073	1,639	1,622	595	1,258	168	-296	662	955	0	0	0
Operating lease liability
-	-200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-17,699	-15,646	-16,819	-18,471	-22,869	-23,233	-24,618	-27,428	-20,362	-22,352	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	115	0	0	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-19,587	-	-14,430	-14,226	-12,301	-9,990	0	0	0
Cash flows from investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of available-for-sale investments
-	-	-	-	-	-	-	-	-	-	-	-	-	39,756	62,264	56,472	54,226	88,644	0	0	0	-	-	-	-
Proceeds from maturities of available-for-sale investments
-	2,500	10,500	18,500	26,975	31,990	31,948	27,948	19,473	16,878	24,260	32,449	51,249	59,943	76,356	92,599	86,158	75,505	0	0	0	-	-	-	-
Proceeds from sale of available-for-sale investments
-	-	-	-	-	1,999	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of available-for-sale investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Purchase of property and equipment
247	16	111	114	126	119	36	42	38	35	35	83	269	271	286	364	201	198	0	0	0	-	-	-	-
Net cash provided by/(used in) investing activities
3,471	2,484	7,897	13,900	11,406	18,427	19,461	-634	-11,508	-16,099	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	33,737	-	-16,870	-41,613	-70,021	-12,483	0	0	0
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs
-	-	-	-	-	-	-	-	-	1,288	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Exercise of stock options
-	-	-	-	-	-	-	-	-	108	150	167	293	197	195	220	100	88	0	0	0	-	-	-	-
Proceeds from - ArTara Private Placement, net of offering costs
0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Proceeds from - Proteon Private Placement, net of offering costs
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from - Series 1 Convertible Preferred Stock, net of offering costs
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments under short-term debt
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
0	-	-	-	-	-	-	-	-	23,049	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net increase/(decrease) in cash and cash equivalents and restricted cash
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	22	400	483	258	180	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in cash, cash equivalents and restricted cash
-	-13,162	-8,876	-1,672	-8,593	-1,799	-1,761	-5,900	-8,776	-15,222	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	175	-	0	0	0	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-40	-90	-47	-75	0	0	0	-	-	-	-
Decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,305	17,369	14,278	-28,809	32,744	8,171	6,198	66,047	0	0	0
Supplemental cash flow information
Cash paid for:
Interest
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of insurance agreement with notes payable
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,353	0	0	0
Fair value of derivative embedded within convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0